barsax - I had read that report last month after someone posted it here. It was quite shocking to see that the mortality rate of the 47K patients discharged from the hospital was 12.3%. This 12.3% is only those that died within 153 days of discharge. How many of the rest of those patients now have compromised organs that will find their lives cut short as a result of them having C19? It's pretty safe to say that if ABL does work the way the CELL report suggests, there is a very large potential market in addition to the diabetic cardio market that ABL is designed to treat.

When looking at the CELL report we can see that it was first published on 28 Oct 2020. Just guessing here but I think the number of deaths in the US alone from then until now is about 350,000. It would seem that RVX isn't the only slow group out there. How many hundreds or even thousands of medical professionals got bogged down in the system and were unable to get apabetalone moved forward on an expedited bases to save a number of those lives that were lost.

Looking forward to the start of dosing of RVX's COVID trial.

tada